Log in to post a reply
Jul 14, 2020 05:53AM
Lumpie
wrote:
Many negative trials presented with 'not-negative conclusions' at oncology meetings
Increased attention should be paid to the conclusions of formally negative trials discussed during oral presentations at oncology meetings, as many convey a not-negative message, according to a research letter published in JAMA Oncology.
"During [the 2019] ASCO Annual Meeting, several trials presented were considered formally negative according to their primary analysis, but they were presented with ambiguous and not-negative conclusions," Massimo Di Maio, MD, researcher in the department of oncology at University of Turin in Torino, Italy, told Healio. "My colleagues and I later decided to perform a systemic review to better understand the real magnitude of this phenomenon. We started with ASCO 2019, but later found that the proportion of those clinical trials was not negligible. We then extended the analysis to the [European Society for Medical Oncology] meeting, covering 3 years in total."
"Our aim was to be provocative," Di Maio said. "We do not want to be considered fundamentalists of clinical research methodology, because we ... know that even in a formally negative trial there could be many potentially important findings and many ideas for further research.
"...It would be interesting to compare the conclusions included in the oral presentation of these trials with the conclusions of their final publication in a peer-reviewed journal. It was too early to perform this analysis when we wrote this letter, but this could be an interesting follow-up."
https://www.healio.com/news/hematology-oncology/20200710/many-negative-trials-presented-with-notnegative-conclusions-at-oncology-meetings?utm_source=selligent&utm_medium=email&utm_campaign=news&m_bt=6155829948217
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride."
Dx
2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC)
Chemotherapy
1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel)
Targeted Therapy
1/14/2016 Herceptin (trastuzumab)
Dx
2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+
Surgery
Lumpectomy: Right
Surgery
Lumpectomy: Right
Radiation Therapy
Whole-breast: Breast